Definitive Contract 75D30121C10819
Award Date
7/16/21
Potential Completion Date
7/15/26
Potential Value
$672K
Federal Agency
CDC Pittsburgh
Awardee
Bioreliance Corporation
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Centers for Disease Control and Prevention in Pittsburgh awarded a purchase order to Bioreliance Corporation's Life Sciences Services Division for $237,266.00 to provide laboratory services, including sterility testing. This firm fixed price contract has a completion date of September 18, 2023. Bioreliance, a foreign-owned for-profit organization, will provide sterility testing using direct inoculation methods, Limulus Amebocyte Lysate (LAL) testing...
This federal contract was awarded to Bioreliance Corporation, a foreign-owned, for-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $6,065,128.00, is a definitive contract with a cost-plus-fixed-fee pricing type. Bioreliance, through its Life Sciences Services Division, will provide a range of specialized testing services to support investigational new drug...
This federal contract award is for a Definitive Contract with a Ceiling Value of $410,000.00. The contract was awarded to Bioreliance Corporation, a foreign-owned, for-profit organization that provides specialized testing services to the U.S. government, particularly the Department of Health and Human Services. The contract is for "BIOMEDICAL (BASIC)" services, which primarily include endotoxin, sterility, and general safety testing in support of investigational new drug...
Bioreliance Corporation, a foreign-owned for-profit organization, was awarded a $34,978 firm-fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) to provide endotoxin, sterility, and general safety testing services in support of investigational new drug (IND) applications for NIAID's Pfs230D1-CRM197 and Pfs230D1-EPA malaria vaccine products. The contract, which does not have a set-aside designation, runs through August 31, 2024. Bioreliance has...
This federal contract award is to Bioreliance Corporation, a foreign-owned, for-profit organization, for the provision of specialized testing services to the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services. The $4,827.00 firm-fixed-price contract is for Bioreliance's Life Sciences Services Division to perform endotoxin, sterility, and general safety testing in support of investigational new drug applications. Bioreliance has extensive...
This federal contract award, valued at $32,797.00, was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Bioreliance Corporation, a foreign-owned, for-profit organization that provides specialized testing services. The contract is for vector biosafety testing, including sterility testing of vector supernatant samples. Bioreliance has a history of supporting various government health initiatives, including providing services to...
This federal contract award was issued by a U.S. government agency to Bioreliance Corporation, a foreign-owned, for-profit organization based in Rockville, Maryland. The $1,710.25 firm-fixed-price contract is for serological testing and polymerase chain reaction (PCR) testing of rats, mice, hamsters, guinea pigs, and animal products for murine pathogens. Bioreliance specializes in providing critical laboratory and testing services to federal agencies, particularly in the pharmaceutical and...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Bioreliance Corporation for endotoxin and sterility testing services. The $16,051.00 firm fixed price contract does not have a set-aside designation, indicating Bioreliance's competitive standing in the field of pharmaceutical and biotechnology research and development. As a foreign-owned, for-profit organization,...
This federal contract award, with ID HHSN272201600262P, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Bioreliance Corporation, a foreign-owned, for-profit organization that specializes in providing critical testing services to the U.S. government. The $9,566.00 fixed-price contract is for endotoxin testing services, which are crucial for advancing health initiatives and drug development processes. Bioreliance, through its Life Sciences Services Division,...
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a Firm Fixed Price Purchase Order to Bioreliance Corporation's Life Sciences Services Division, doing business as Bioreliance Corp De, for $15,434.00 in endotoxin and sterility testing services. The contract, which has a completion date of June 12, 2024, is to provide isolator sterility testing, Limulus Amebocyte Lysate (LAL) testing for...